Regulatory Norgine gets first EU approval for WHIM syndrome therapy PharmaphorumPatients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.Rare DiseaseRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine’s Xolremdi. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Regeneron Q1 2026 net income falls 10% to $727mNext: GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
